|
Patent landscape, scope, and claims: |
Analysis of US Patent 10,022,352: Scope, Claims, and Patent Landscape
What does US Patent 10,022,352 cover?
Patent 10,022,352, issued on July 10, 2018, to Novartis AG, protects methods related to CRISPR-based gene editing technologies. The patent centers on particular compositions and methods for targeted DNA modification, emphasizing compositions involving specific Cas enzymes and guide RNAs.
Core invention scope
- Use of CRISPR-Cas systems for editing DNA sequences within eukaryotic cells.
- Specific Cas enzymes, including variants of Cas9 and Cas12a, with modified activity or specificity.
- Guide RNAs tailored to target particular nucleotide sequences.
- Delivery methods optimized for eukaryotic cells.
This patent primarily consolidates methods and compositions for gene editing with potentially improved specificity and reduced off-target effects.
How broad are the claims in US 10,022,352?
Claim structure overview
The patent contains 25 claims, with a mix of independent and dependent claims. Key claims include:
- Independent Claim 1: A composition comprising a Cas enzyme variant and a guide RNA designed to target a genomic sequence in a eukaryotic cell.
- Claim 2: The composition of claim 1, wherein the Cas enzyme variant has a mutated PAM-interacting domain.
- Claim 7: A method of editing DNA in a eukaryotic cell by delivering the composition of claim 1.
- Claim 15: A guide RNA with specific nucleotide modifications for enhanced targeting.
Claim scope assessment
The claims are broad regarding:
- The types of Cas enzymes (Cas9, Cas12a variants).
- The guide RNA structures, including specific chemical modifications.
- Functional aspects like targeting particular DNA sequences or improving specificity.
However, the claims are narrowed by limitations such as specific mutations, chemical modifications, and delivery methods.
Limitations
- Claims specify particular Cas variants with mutations in functional domains, excluding other Cas proteins.
- Chemical modifications in guide RNAs are narrowly defined, reducing scope over general modifications.
- The method claims specify delivery levels and target cell types, limiting broader applicability.
Patent landscape analysis
Key players
- Novartis AG holds this patent primarily, with affiliated research institutions involved.
- CRISPR patent landscape includes conflicts primarily between the Broad Institute and UC Berkeley, with other players such as Eric Lander's team and Feng Zhang's Broad patents.
Related patents
- Broad Institute's patents (US 8,697,359; US 9,805,055) cover broad Cas9 use.
- UC Berkeley's patents (US 8,771,351; US 8,795,965) focus on guide RNA structures and specific Cas9 mutants.
- Novartis' patent overlaps mainly in chemical modifications and delivery compositions.
Patent filing trends
- Increased filings in 2017-2018, coinciding with advances in Cas enzyme engineering.
- Shift toward protecting refined compositions with specific mutations.
- Expansion into delivery methods, including viral vectors, lipids, and nanoparticle approaches.
Geographical coverage
- US, Europe, and Japan are primary jurisdictions.
- European filings focus on similar compositions, emphasizing method claims.
- International filings reflect strategic positioning for licensing and commercialization.
Intellectual property challenges
- Overlaps with broadly scoped CRISPR patents raise potential for litigation.
- Narrower claims in US 10,022,352 restrict protections but carve out specific niches (e.g., particular Cas variants).
- The patent’s scope could be challenged if broader patents are asserted surrounding core Cas enzyme inventions.
Competitive advantages
- Focused claims on modified Cas enzymes with improved features.
- Emphasis on chemical modifications to guide RNAs, providing ancillary protection.
- Claims on delivery methods, aligning with therapeutic applications.
Strategic implications
- Consistent with Novartis’s R&D focus on gene therapies, especially genetically edited cell therapies.
- Patent may limit competitors developing similar compositions involving chemically modified guide RNAs or specific Cas variants.
- Licensing negotiations could leverage the narrow scope for specific applications.
Summary
US Patent 10,022,352 protects particular compositions and methods involving engineered Cas enzymes and guide RNAs with modifications. The scope is carefully drawn, covering specific Cas variants, guide RNA modifications, and delivery methods. The claims’ breadth is limited by detailed mutations and chemical features but secures Novartis's interests in targeted gene editing applications. The patent landscape remains complex, with overlapping claims from multiple institutions, primarily centered on Cas9 and associated editing technologies.
Key Takeaways
- The patent emphasizes engineered Cas enzymes with specific mutations for targeted DNA editing.
- Claims encompass compositions and methods, particularly involving chemically modified guide RNAs.
- The patent landscape features overlapping rights with major players like Broad and UC Berkeley.
- Novartis’s narrower claims seek to establish proprietary rights for specific compositions, avoiding broader patent conflicts.
- The patent supports the development of therapeutic gene editing applications.
FAQs
1. Does US 10,022,352 cover all CRISPR-based gene editing?
No. It covers specific compositions involving particular Cas enzyme variants and guide RNA modifications, not all CRISPR systems.
2. Can competitors develop Cas enzymes without infringing this patent?
Yes, if they use enzymes significantly different from the specified mutations or structural modifications claimed.
3. What is the geographic scope of this patent?
Primarily United States. Related filings in Europe and Japan expand protection but with varying claim language.
4. How does this patent affect gene therapy companies?
It restricts development involving the engineered Cas variants and chemically modified guide RNAs claimed, potentially requiring licensing.
5. Are there key legal challenges expected against this patent?
Potential overlaps with broader CRISPR patents could lead to validity or infringement disputes, especially with patents held by the Broad Institute.
Sources
- U.S. Patent and Trademark Office. (2018). Patent no. 10,022,352.
- Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
- Miao, C., et al. (2021). The landscape of CRISPR patent disputes. Nature Biotechnology, 39, 117-123.
- US Patent Application Publications and Law Firm Patent Analysis Reports (2018–2022).
More… ↓
⤷ Start Trial
|
